MyelinWatch EL
← Studies & programmes
Emerging treatmentsMyelin repair
Results from peopleUnknownMixed findings

Phase 2 study and expanded-access programme

MSC-NP / Tisch

Research group
Tisch Multiple Sclerosis Research Center of New York · United States
Funder
National Multiple Sclerosis Society and the Damial Foundation
Researcher
Violaine K. Harris

Autologous mesenchymal stem cell-derived neural progenitors (MSC-NP), given into spinal fluid

Treatment or approach
Autologous mesenchymal stem cell-derived neural progenitors (MSC-NP), given into spinal fluid
How it is intended to work
Autologous mesenchymal stem cell-derived neural progenitors (MSC-NP)
Current research stage
Phase 2 study and expanded-access programme
What is happening now?
A published biomarker analysis reports on two progressive MS cohorts; the current programme status is not established here
What kind of evidence exists?
Biomarker analysis in people • CSF changes are not proof of benefit to patients

What we know

Biomarker analysis in people • CSF changes are not proof of benefit to patients

What this means for patients

This record describes research, not a personalised treatment recommendation. Availability must be confirmed for the relevant country, indication and study site.

Practical availability: Research only — not an established treatment

Source: Stem Cells Translational Medicine / Tisch Multiple Sclerosis Research Center of New York — peer-reviewed primary article ↗
Published by MyelinWatch
Last substantive MyelinWatch update

Related substantive developments

Emerging treatmentsMyelin repair
Results from peopleCompletedBiological signal in biomarkers, not proof of clinical benefit

Results from people

MSC-NP study finds CSF biomarker changes in two progressive MS cohorts

Research group: Tisch Multiple Sclerosis Research Center of New York · United States

A published analysis examined cerebrospinal-fluid samples from two groups of people with secondary or primary progressive MS: 50 participants in a Phase 2 study and 43 in an expanded-access programme. After repeated intrathecal autologous MSC-NP treatment, CCL2, MMP9, SCF and CHIT1 changed in cerebrospinal fluid. NfL and GFAP did not show the same pattern of change.

What this means for people with MS

These findings may help measure biological response and guide future study design. They do not show remyelination, improvement in symptoms or disability, or an established benefit to patients.

Read the update →Source: Stem Cells Translational Medicine / Tisch Multiple Sclerosis Research Center of New York — peer-reviewed primary article ↗